149
Participants
Start Date
February 28, 2015
Primary Completion Date
March 29, 2018
Study Completion Date
March 29, 2018
Rociletinib
Pemetrexed or gemcitabine or paclitaxel or docetaxel
Royal North Shore Hospital, Saint Leonards
Westmead Hospital, Westmead
Flinders Medical Centre, Bedford Park
National Taiwan University Hospital, Taipei
A.O.U. San Luigi Gonzaga di Orbassano, Orbassano
Taipei Veterans General Hospital, Taipei
L'Assistance Publique - Hopitaux de Marseille, Marseille
Centre François Baclesse, Caen
Roswell Park Cancer Institute, Buffalo
University of Pittsburgh Cancer Institute (UPMC), Pittsburgh
IRCCS Azienda Ospedaliera Universitaria San Martino - IST, Genova
Istituto Europeo di Oncologia, Milan
Walter Reed National Military Medical Center, Bethesda
University of Virginia, Charlottesville
LungenClinic Großhansdorf GmbH, Großhansdorf
Virginia Cancer Institute, Richmond
Pius Hospital Oldenburg, Oldenburg
Fundacion Jimenez Diaz (Clinica de la Concepcion) (UAM -FJD), Madrid
Hospital Regional Universitario Carlos Haya, Málaga
Northside Hospital, Atlanta
Johannes-Wesling-Klinikum Minden, Minden
University of Florida Health Science Center, Gainesville
Memorial Healthcare System, Pembroke Pines
Sylvester Comprehensive Cancer Center (UMHC), Deerfield Beach
Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, Rennes
China Medical University Hospital, Taichung
Taichung Veterans General Hospital, Taichung
Hospital Universitario Virgen del Rocio, Seville
The Ohio State University Comprehensive Cancer Center, Columbus
Saint Joseph Mercy Hospital, Ann Arbor
Barbara Ann Karmanos Cancer Institute, Detroit
Azienda Ospedaliero-Universitaria Careggi, Florence
Virginia Piper Cancer Institute, Minneapolis
Ospedale Civile di Livorno, Livorno
CHRU de Lille - Hôpital Calmette, Lille
North Shore University Health System, Evanston
Hopital Hautepierre (CHU) de Strasbourg, Strasbourg
Thoraxklinik Heidelberg gGmbH, Heidelberg
Centre Léon Bérard, Lyon
National Cheng-Kung University Hospital, Tainan City
Hôpital Bichat-Claude Bernard, Paris
University of Texas Southwestern Medical Center, Dallas
LMU - Klinikum der Universität München, München
Asklepios Fachkliniken München-Gauting, Gauting
Huntsman Cancer Institute, Salt Lake City
CHRU de Limoges - Hôpital Dupuytren, Limoges
Cancer Care Associates Medical Group, Inc., Redondo Beach
University of California at Los Angeles, Santa Monica
The Oncology Institute of Hope and Innovation, Whittier
City of Hope Cancer Center, Duarte
Saint Joseph Heritage Healthcare, Fullerton
Comprehensive Blood and Cancer Center, Bakersfield
Central Coast Medical Oncology Corporation, Santa Maria
Centre Hospitalier Intercommunal Créteil, Créteil
University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco
Stanford University School of Medicine, Stanford
Sutter Cancer Center, Sacramento
Providence Health and Services, Portland
Oregon Health & Science University (OHSU) - Knight Cancer Institute, Portland
University of California San Diego Moores Cancer Center, La Jolla
Regional Cancer Care Associates, LLC, East Brunswick
Regional Cancer Care Associates, Morristown
Azienda Ospedaliera di Perugia, Perugia
Academisch Ziekenhuis Maastricht, Maastricht
Antoni van Leeuwenhoek Hospital, Amsterdam
Universitair Medisch Centrum Groningen, Groningen
Chungbuk National University Hospital, Cheongju-si
Seoul National University Bundang Hospital, Seongnam-si
The Catholic University of Korea Saint Vincent's Hospital, Suwon
Chonnam National University Hwasun Hospital, Hwasun-gun
Samsung Medical Center, Seoul
Asan Medical Center, Seoul
Hospital Universitari Germans Trias i Pujol, Badalona
Hospital de Mataró, Mataró
Institut Universitari Dexeus, Barcelona
Hospital Universitari Vall D'Hebron, Barcelona
University College London Hospitals, London
Guy's and Saint Thomas NHS Foundation Trust, London
Royal Marsden NHS Trust, London
The Christie NHS Foundation Trust, Manchester
Lead Sponsor
Clovis Oncology, Inc.
INDUSTRY